Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma-Reference-Cited by-同舟云学术

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

Published:2016-12-22 Issue:5 Volume:176 Page:783-795
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Raje Noopur S.¹,Moreau Philippe²,Terpos Evangelos³,Benboubker Lotfi⁴,Grząśko Norbert⁵,Holstein Sarah A.⁶,Oriol Albert⁷,Huang Shang-Yi⁸,Beksac Meral⁹,Kuliczkowski Kazimierz¹⁰,Tai Datchen F.¹¹,Wooldridge James E.¹¹,Conti Ilaria¹¹,Kaiser Christopher J.¹¹,Nguyen Tuan S.¹¹,Cronier Damien M.¹²,Palumbo Antonio¹³

Affiliation:

1. Massachusetts General Hospital; Boston MA USA

2. University Hospital Hôtel-Dieu; Nantes France

3. National and Kapodistrian University of Athens School of Medicine; Athens Greece

4. Hôpital Bretonneau; Centre Hospitalier Régional Universitaire (CHRU); Tours France

5. Medical University of Lublin and Department of Haematology; St. John's Cancer Centre; Lublin Poland

6. Roswell Park Cancer Institute; Buffalo NY USA

7. Institut Català d'Oncologia (ICO) and Institut de Recerca contra la Leucèmia Josep Carreras (IJC); Hospital Germans Trias i Pujol; Badalona Spain

8. National Taiwan University; Medical College and Hospital; Taipei Taiwan

9. Ankara University Ibn Sina Hospital; Ankara Turkey

10. Wroclaw Medical University; Wroclaw Poland

11. Eli Lilly and Company; Indianapolis IN USA

12. Eli Lilly and Company Limited; Windlesham Surrey UK

13. Myeloma Unit; Division of Haematology; University of Torino; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino; Torino Italy

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14483/fullpdf

Reference49 articles.

1. Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma;Alexandrakis;BioMed Research International,2013

2. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Erratum published in Blood. 2009;113:4478;Argyriou;Blood,2008

3. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma;Berdeja;Haematologica,2015